APO Research
Talk to an analyst

APO RESEARCH · REPORT

Conjugate Vaccine

Vaccines are used to prevent diseases by invoking an immune response to an antigen, the foreign part of a bacteria or virus that the immune system recognizes. Conjugate vaccines combine a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Vaccines are used to prevent diseases by invoking an immune response to an antigen, the foreign part of a bacteria or virus that the immune system recognizes. Conjugate vaccines combine a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.

Selected research

Market Analysis & Forecast

Global Conjugate Vaccine Market Analysis and Forecast 2026-2032

27 December 2025199 pages

Choose your research edition.

Industry ResearchConjugate Vaccine Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Conjugate Vaccine Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Conjugate Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Conjugate Vaccine Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Conjugate Vaccine Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Vaccines are used to prevent diseases by invoking an immune response to an antigen, the foreign part of a bacteria or virus that the immune system recognizes. Conjugate vaccines combine a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.

Market competition is intense. Pfizer, GSK, Sanofi, Merck, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. Top 5 manufacturers accounted for 86.11% market share in 2019.

This report presents an overview of global market for Conjugate Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

Read the full market overview

This report researches the key producers of Conjugate Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Conjugate Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Conjugate Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Conjugate Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Conjugate Vaccine sales, projected growth trends, production technology, application and end-user industry.

Conjugate Vaccine Segment by Company

Pfizer

GSK

Sanofi

Merck

Walvax Biotechnology

Royal (Wuxi) Bio-Pharmaceutical

Bharat Biotech

Zhifei Biologic

Conjugate Vaccine Segment by Type

Hib Vaccine

Meningococcal Vaccine

Pneumococcal Vaccine

Others

Conjugate Vaccine Segment by End Users

Children

Adult

Conjugate Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Conjugate Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Conjugate Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Conjugate Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Conjugate Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Conjugate Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Conjugate Vaccine sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Conjugate Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Hib Vaccine Major Manufacturers Table 3. Meningococcal Vaccine Major Manufacturers Table 4. Pneumococcal Vaccine Major Manufacturers Table 5. Others Major Manufacturers Table 6. Global Conjugate Vaccine Market Size Growth Rate by End Users (US$ Million), 2021 VS 2025 VS 2032 Table 7. Children Major Manufacturers Table 8. Adult Major Manufacturers Table 9. Conjugate Vaccine Industry Trends Table 10. Conjugate Vaccine Industry Drivers Table 11. Conjugate Vaccine Industry Opportunities and Challenges Table 12. Conjugate Vaccine Industry Restraints Table 13. Global Conjugate Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global Conjugate Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 15. Global Conjugate Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 16. Global Conjugate Vaccine Revenue Market Share by Region (2021-2026) Table 17. Global Conjugate Vaccine Revenue Market Share by Region (2027-2032) Table 18. Global Conjugate Vaccine Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (Million Unit) Table 19. Global Conjugate Vaccine Sales by Region (2021-2026) & (Million Unit) Table 20. Global Conjugate Vaccine Sales by Region (2027-2032) & (Million Unit) Table 21. Global Conjugate Vaccine Sales Market Share by Region (2021-2026) Table 22. Global Conjugate Vaccine Sales Market Share by Region (2027-2032) Table 23. Global Conjugate Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Conjugate Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 25. Global Conjugate Vaccine Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Conjugate Vaccine Sales Market Share by Manufacturers (2021-2026) Table 27. Global Conjugate Vaccine Sales Price (USD/Unit) of Manufacturers (2021-2026) Table 28. Global Conjugate Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global Conjugate Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global Conjugate Vaccine Manufacturers, Product Type & Application Table 31. Global Conjugate Vaccine Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Conjugate Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global Conjugate Vaccine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Conjugate Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 36. Global Conjugate Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 37. Global Conjugate Vaccine Revenue Market Share by Type (2021-2026) Table 38. Global Conjugate Vaccine Revenue Market Share by Type (2027-2032) Table 39. Global Conjugate Vaccine Sales by Type 2021 VS 2025 VS 2032 (Million Unit) Table 40. Global Conjugate Vaccine Sales by Type (2021-2026) & (Million Unit) Table 41. Global Conjugate Vaccine Sales by Type (2027-2032) & (Million Unit) Table 42. Global Conjugate Vaccine Sales Market Share by Type (2021-2026) Table 43. Global Conjugate Vaccine Sales Market Share by Type (2027-2032) Table 44. Global Conjugate Vaccine Price by Type (2021-2026) & (USD/Unit) Table 45. Global Conjugate Vaccine Price by Type (2027-2032) & (USD/Unit) Table 46. Global Conjugate Vaccine Revenue by End Users 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Conjugate Vaccine Revenue by End Users (2021-2026) & (US$ Million) Table 48. Global Conjugate Vaccine Revenue by End Users (2027-2032) & (US$ Million) Table 49. Global Conjugate Vaccine Revenue Market Share by End Users (2021-2026) Table 50. Global Conjugate Vaccine Revenue Market Share by End Users (2027-2032) Table 51. Global Conjugate Vaccine Sales by End Users 2021 VS 2025 VS 2032 (Million Unit) Table 52. Global Conjugate Vaccine Sales by End Users (2021-2026) & (Million Unit) Table 53. Global Conjugate Vaccine Sales by End Users (2027-2032) & (Million Unit) Table 54. Global Conjugate Vaccine Sales Market Share by End Users (2021-2026) Table 55. Global Conjugate Vaccine Sales Market Share by End Users (2027-2032) Table 56. Global Conjugate Vaccine Price by End Users (2021-2026) & (USD/Unit) Table 57. Global Conjugate Vaccine Price by End Users (2027-2032) & (USD/Unit) Table 58. Pfizer Company Information Table 59. Pfizer Business Overview Table 60. Pfizer Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 61. Pfizer Conjugate Vaccine Product Portfolio Table 62. Pfizer Recent Development Table 63. GSK Company Information Table 64. GSK Business Overview Table 65. GSK Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 66. GSK Conjugate Vaccine Product Portfolio Table 67. GSK Recent Development Table 68. Sanofi Company Information Table 69. Sanofi Business Overview Table 70. Sanofi Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 71. Sanofi Conjugate Vaccine Product Portfolio Table 72. Sanofi Recent Development Table 73. Merck Company Information Table 74. Merck Business Overview Table 75. Merck Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 76. Merck Conjugate Vaccine Product Portfolio Table 77. Merck Recent Development Table 78. Walvax Biotechnology Company Information Table 79. Walvax Biotechnology Business Overview Table 80. Walvax Biotechnology Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 81. Walvax Biotechnology Conjugate Vaccine Product Portfolio Table 82. Walvax Biotechnology Recent Development Table 83. Royal (Wuxi) Bio-Pharmaceutical Company Information Table 84. Royal (Wuxi) Bio-Pharmaceutical Business Overview Table 85. Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 86. Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Product Portfolio Table 87. Royal (Wuxi) Bio-Pharmaceutical Recent Development Table 88. Bharat Biotech Company Information Table 89. Bharat Biotech Business Overview Table 90. Bharat Biotech Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 91. Bharat Biotech Conjugate Vaccine Product Portfolio Table 92. Bharat Biotech Recent Development Table 93. Zhifei Biologic Company Information Table 94. Zhifei Biologic Business Overview Table 95. Zhifei Biologic Conjugate Vaccine Sales (Million Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 96. Zhifei Biologic Conjugate Vaccine Product Portfolio Table 97. Zhifei Biologic Recent Development Table 98. North America Conjugate Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 99. North America Conjugate Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 100. North America Conjugate Vaccine Sales by Type (2021-2026) & (Million Unit) Table 101. North America Conjugate Vaccine Sales by Type (2027-2032) & (Million Unit) Table 102. North America Conjugate Vaccine Sales Price by Type (2021-2026) & (USD/Unit) Table 103. North America Conjugate Vaccine Sales Price by Type (2027-2032) & (USD/Unit) Table 104. North America Conjugate Vaccine Revenue by End Users (2021-2026) & (US$ Million) Table 105. North America Conjugate Vaccine Revenue by End Users (2027-2032) & (US$ Million) Table 106. North America Conjugate Vaccine Sales by End Users (2021-2026) & (Million Unit) Table 107. North America Conjugate Vaccine Sales by End Users (2027-2032) & (Million Unit) Table 108. North America Conjugate Vaccine Sales Price by End Users (2021-2026) & (USD/Unit) Table 109. North America Conjugate Vaccine Sales Price by End Users (2027-2032) & (USD/Unit) Table 110. North America Conjugate Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 111. North America Conjugate Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 112. North America Conjugate Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 113. North America Conjugate Vaccine Sales by Country (2021 VS 2025 VS 2032) & (Million Unit) Table 114. North America Conjugate Vaccine Sales by Country (2021-2026) & (Million Unit) Table 115. North America Conjugate Vaccine Sales by Country (2027-2032) & (Million Unit) Table 116. North America Conjugate Vaccine Sales Price by Country (2021-2026) & (USD/Unit) Table 117. North America Conjugate Vaccine Sales Price by Country (2027-2032) & (USD/Unit) Table 118. United States Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 119. Canada Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 120. Mexico Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 121. Europe Conjugate Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 122. Europe Conjugate Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 123. Europe Conjugate Vaccine Sales by Type (2021-2026) & (Million Unit) Table 124. Europe Conjugate Vaccine Sales by Type (2027-2032) & (Million Unit) Table 125. Europe Conjugate Vaccine Sales Price by Type (2021-2026) & (USD/Unit) Table 126. Europe Conjugate Vaccine Sales Price by Type (2027-2032) & (USD/Unit) Table 127. Europe Conjugate Vaccine Revenue by End Users (2021-2026) & (US$ Million) Table 128. Europe Conjugate Vaccine Revenue by End Users (2027-2032) & (US$ Million) Table 129. Europe Conjugate Vaccine Sales by End Users (2021-2026) & (Million Unit) Table 130. Europe Conjugate Vaccine Sales by End Users (2027-2032) & (Million Unit) Table 131. Europe Conjugate Vaccine Sales Price by End Users (2021-2026) & (USD/Unit) Table 132. Europe Conjugate Vaccine Sales Price by End Users (2027-2032) & (USD/Unit) Table 133. Europe Conjugate Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 134. Europe Conjugate Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 135. Europe Conjugate Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 136. Europe Conjugate Vaccine Sales by Country (2021 VS 2025 VS 2032) & (Million Unit) Table 137. Europe Conjugate Vaccine Sales by Country (2021-2026) & (Million Unit) Table 138. Europe Conjugate Vaccine Sales by Country (2027-2032) & (Million Unit) Table 139. Europe Conjugate Vaccine Sales Price by Country (2021-2026) & (USD/Unit) Table 140. Europe Conjugate Vaccine Sales Price by Country (2027-2032) & (USD/Unit) Table 141. Germany Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 142. France Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 143. U.K. Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 144. Italy Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 145. Russia Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 146. Spain Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 147. Netherlands Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 148. Switzerland Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 149. Sweden Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 150. Poland Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 151. China Conjugate Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 152. China Conjugate Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 153. China Conjugate Vaccine Sales by Type (2021-2026) & (Million Unit) Table 154. China Conjugate Vaccine Sales by Type (2027-2032) & (Million Unit) Table 155. China Conjugate Vaccine Sales Price by Type (2021-2026) & (USD/Unit) Table 156. China Conjugate Vaccine Sales Price by Type (2027-2032) & (USD/Unit) Table 157. China Conjugate Vaccine Revenue by End Users (2021-2026) & (US$ Million) Table 158. China Conjugate Vaccine Revenue by End Users (2027-2032) & (US$ Million) Table 159. China Conjugate Vaccine Sales by End Users (2021-2026) & (Million Unit) Table 160. China Conjugate Vaccine Sales by End Users (2027-2032) & (Million Unit) Table 161. China Conjugate Vaccine Sales Price by End Users (2021-2026) & (USD/Unit) Table 162. China Conjugate Vaccine Sales Price by End Users (2027-2032) & (USD/Unit) Table 163. Asia Conjugate Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 164. Asia Conjugate Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 165. Asia Conjugate Vaccine Sales by Type (2021-2026) & (Million Unit) Table 166. Asia Conjugate Vaccine Sales by Type (2027-2032) & (Million Unit) Table 167. Asia Conjugate Vaccine Sales Price by Type (2021-2026) & (USD/Unit) Table 168. Asia Conjugate Vaccine Sales Price by Type (2027-2032) & (USD/Unit) Table 169. Asia Conjugate Vaccine Revenue by End Users (2021-2026) & (US$ Million) Table 170. Asia Conjugate Vaccine Revenue by End Users (2027-2032) & (US$ Million) Table 171. Asia Conjugate Vaccine Sales by End Users (2021-2026) & (Million Unit) Table 172. Asia Conjugate Vaccine Sales by End Users (2027-2032) & (Million Unit) Table 173. Asia Conjugate Vaccine Sales Price by End Users (2021-2026) & (USD/Unit) Table 174. Asia Conjugate Vaccine Sales Price by End Users (2027-2032) & (USD/Unit) Table 175. Asia Conjugate Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 176. Asia Conjugate Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 177. Asia Conjugate Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 178. Asia Conjugate Vaccine Sales by Country (2021 VS 2025 VS 2032) & (Million Unit) Table 179. Asia Conjugate Vaccine Sales by Country (2021-2026) & (Million Unit) Table 180. Asia Conjugate Vaccine Sales by Country (2027-2032) & (Million Unit) Table 181. Asia Conjugate Vaccine Sales Price by Country (2021-2026) & (USD/Unit) Table 182. Asia Conjugate Vaccine Sales Price by Country (2027-2032) & (USD/Unit) Table 183. Japan Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 184. South Korea Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 185. India Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 186. Australia Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 187. Taiwan Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 188. Southeast Asia Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 189. SAMEA Conjugate Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 190. SAMEA Conjugate Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 191. SAMEA Conjugate Vaccine Sales by Type (2021-2026) & (Million Unit) Table 192. SAMEA Conjugate Vaccine Sales by Type (2027-2032) & (Million Unit) Table 193. SAMEA Conjugate Vaccine Sales Price by Type (2021-2026) & (USD/Unit) Table 194. SAMEA Conjugate Vaccine Sales Price by Type (2027-2032) & (USD/Unit) Table 195. SAMEA Conjugate Vaccine Revenue by End Users (2021-2026) & (US$ Million) Table 196. SAMEA Conjugate Vaccine Revenue by End Users (2027-2032) & (US$ Million) Table 197. SAMEA Conjugate Vaccine Sales by End Users (2021-2026) & (Million Unit) Table 198. SAMEA Conjugate Vaccine Sales by End Users (2027-2032) & (Million Unit) Table 199. SAMEA Conjugate Vaccine Sales Price by End Users (2021-2026) & (USD/Unit) Table 200. SAMEA Conjugate Vaccine Sales Price by End Users (2027-2032) & (USD/Unit) Table 201. SAMEA Conjugate Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 202. SAMEA Conjugate Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 203. SAMEA Conjugate Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 204. SAMEA Conjugate Vaccine Sales by Country (2021 VS 2025 VS 2032) & (Million Unit) Table 205. SAMEA Conjugate Vaccine Sales by Country (2021-2026) & (Million Unit) Table 206. SAMEA Conjugate Vaccine Sales by Country (2027-2032) & (Million Unit) Table 207. SAMEA Conjugate Vaccine Sales Price by Country (2021-2026) & (USD/Unit) Table 208. SAMEA Conjugate Vaccine Sales Price by Country (2027-2032) & (USD/Unit) Table 209. Brazil Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 210. Argentina Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 211. Chile Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 212. Colombia Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 213. Peru Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 214. Saudi Arabia Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 215. Israel Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 216. UAE Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 217. Turkey Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 218. Iran Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 219. Egypt Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 220. Key Raw Materials Table 221. Raw Materials Key Suppliers Table 222. Conjugate Vaccine Distributors List Table 223. Conjugate Vaccine Customers List Table 224. Research Programs/Design for This Report Table 225. Authors List of This Report Table 226. Secondary Sources Table 227. Primary Sources List of Figures Figure 1. Conjugate Vaccine Image Figure 2. Global Conjugate Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Conjugate Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Hib Vaccine Image Figure 5. Meningococcal Vaccine Image Figure 6. Pneumococcal Vaccine Image Figure 7. Others Image Figure 8. Global Conjugate Vaccine Market Size Growth Rate by End Users (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Conjugate Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 10. Children Image Figure 11. Adult Image Figure 12. Global Conjugate Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Figure 14. Global Conjugate Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global Conjugate Vaccine Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global Conjugate Vaccine Revenue Market Share by Region (2021-2032) Figure 17. Global Conjugate Vaccine Sales (2021-2032) & (Million Unit) Figure 18. Global Conjugate Vaccine Sales by Region: 2021 VS 2025 VS 2032 (Million Unit) Figure 19. Global Conjugate Vaccine Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico Conjugate Vaccine Sales YoY (2021-2032) & (Million Unit) Figure 21. Europe Conjugate Vaccine Sales YoY (2021-2032) & (Million Unit) Figure 22. China Conjugate Vaccine Sales YoY (2021-2032) & (Million Unit) Figure 23. Asia (Excluding China) Conjugate Vaccine Sales YoY (2021-2032) & (Million Unit) Figure 24. South America, Middle East and Africa Conjugate Vaccine Sales YoY (2021-2032) & (Million Unit) Figure 25. Global Conjugate Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global Conjugate Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global Conjugate Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Conjugate Vaccine Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 30. Global Conjugate Vaccine Revenue Market Share by Type (2021-2032) Figure 31. Global Conjugate Vaccine Sales by Type (2021 VS 2025 VS 2032) & (Million Unit) Figure 32. Global Conjugate Vaccine Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Conjugate Vaccine Sales Market Share by Type (2021-2032) Figure 34. Global Conjugate Vaccine Revenue by End Users (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global Conjugate Vaccine Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 36. Global Conjugate Vaccine Revenue Market Share by End Users (2021-2032) Figure 37. Global Conjugate Vaccine Sales by End Users (2021 VS 2025 VS 2032) & (Million Unit) Figure 38. Global Conjugate Vaccine Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Conjugate Vaccine Sales Market Share by End Users (2021-2032) Figure 40. North America Conjugate Vaccine Revenue Share by Type (2021-2032) Figure 41. North America Conjugate Vaccine Sales Share by Type (2021-2032) Figure 42. North America Conjugate Vaccine Revenue Share by End Users (2021-2032) Figure 43. North America Conjugate Vaccine Sales Share by End Users (2021-2032) Figure 44. North America Conjugate Vaccine Revenue Share by Country (2021-2032) Figure 45. North America Conjugate Vaccine Sales Share by Country (2021-2032) Figure 46. Europe Conjugate Vaccine Revenue Share by Type (2021-2032) Figure 47. Europe Conjugate Vaccine Sales Share by Type (2021-2032) Figure 48. Europe Conjugate Vaccine Revenue Share by End Users (2021-2032) Figure 49. Europe Conjugate Vaccine Sales Share by End Users (2021-2032) Figure 50. Europe Conjugate Vaccine Revenue Share by Country (2021-2032) Figure 51. Europe Conjugate Vaccine Sales Share by Country (2021-2032) Figure 52. China Conjugate Vaccine Revenue Share by Type (2021-2032) Figure 53. China Conjugate Vaccine Sales Share by Type (2021-2032) Figure 54. China Conjugate Vaccine Revenue Share by End Users (2021-2032) Figure 55. China Conjugate Vaccine Sales Share by End Users (2021-2032) Figure 56. Asia Conjugate Vaccine Revenue Share by Type (2021-2032) Figure 57. Asia Conjugate Vaccine Sales Share by Type (2021-2032) Figure 58. Asia Conjugate Vaccine Revenue Share by End Users (2021-2032) Figure 59. Asia Conjugate Vaccine Sales Share by End Users (2021-2032) Figure 60. Asia Conjugate Vaccine Revenue Share by Country (2021-2032) Figure 61. Asia Conjugate Vaccine Sales Share by Country (2021-2032) Figure 62. SAMEA Conjugate Vaccine Revenue Share by Type (2021-2032) Figure 63. SAMEA Conjugate Vaccine Sales Share by Type (2021-2032) Figure 64. SAMEA Conjugate Vaccine Revenue Share by End Users (2021-2032) Figure 65. SAMEA Conjugate Vaccine Sales Share by End Users (2021-2032) Figure 66. SAMEA Conjugate Vaccine Revenue Share by Country (2021-2032) Figure 67. SAMEA Conjugate Vaccine Sales Share by Country (2021-2032) Figure 68. Conjugate Vaccine Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Conjugate Vaccine Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Hib Vaccine
  • Meningococcal Vaccine
  • Pneumococcal Vaccine
  • Others
Applications
  • Children
  • Adult
Companies covered
  • Pfizer
  • GSK
  • Sanofi
  • Merck
  • Walvax Biotechnology
  • Royal (Wuxi) Bio-Pharmaceutical
  • Bharat Biotech
  • Zhifei Biologic

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Conjugate Vaccine Market by Type
  3. 1.2.1 Global Conjugate Vaccine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Hib Vaccine
  5. 1.2.3 Meningococcal Vaccine
  6. 1.2.4 Pneumococcal Vaccine
  7. 1.2.5 Others
  8. 1.3 Conjugate Vaccine Market by End Users
  9. 1.3.1 Global Conjugate Vaccine Market Size by End Users, 2021 VS 2025 VS 2032
  10. 1.3.2 Children
  11. 1.3.3 Adult
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Conjugate Vaccine Market Dynamics
  1. 2.1 Conjugate Vaccine Industry Trends
  2. 2.2 Conjugate Vaccine Industry Drivers
  3. 2.3 Conjugate Vaccine Industry Opportunities and Challenges
  4. 2.4 Conjugate Vaccine Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Conjugate Vaccine Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Conjugate Vaccine Revenue by Region
  3. 3.2.1 Global Conjugate Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Conjugate Vaccine Revenue by Region (2021-2026)
  5. 3.2.3 Global Conjugate Vaccine Revenue by Region (2027-2032)
  6. 3.2.4 Global Conjugate Vaccine Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Conjugate Vaccine Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Conjugate Vaccine Sales by Region
  9. 3.4.1 Global Conjugate Vaccine Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Conjugate Vaccine Sales by Region (2021-2026)
  11. 3.4.3 Global Conjugate Vaccine Sales by Region (2027-2032)
  12. 3.4.4 Global Conjugate Vaccine Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Conjugate Vaccine Revenue by Manufacturers
  2. 4.1.1 Global Conjugate Vaccine Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Conjugate Vaccine Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Conjugate Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Conjugate Vaccine Sales by Manufacturers
  6. 4.2.1 Global Conjugate Vaccine Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Conjugate Vaccine Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Conjugate Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Conjugate Vaccine Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Conjugate Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Conjugate Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Conjugate Vaccine Manufacturers, Product Type & Application
  13. 4.7 Global Conjugate Vaccine Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Conjugate Vaccine Market CR5 and HHI
  16. 4.8.2 2025 Conjugate Vaccine Tier 1, Tier 2, and Tier 3
5 Conjugate Vaccine Market by Type
  1. 5.1 Global Conjugate Vaccine Revenue by Type
  2. 5.1.1 Global Conjugate Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Conjugate Vaccine Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Conjugate Vaccine Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Conjugate Vaccine Sales by Type
  6. 5.2.1 Global Conjugate Vaccine Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Conjugate Vaccine Sales by Type (2021-2032) & (Million Unit)
  8. 5.2.3 Global Conjugate Vaccine Sales Market Share by Type (2021-2032)
  9. 5.3 Global Conjugate Vaccine Price by Type
6 Conjugate Vaccine Market by Application
  1. 6.1 Global Conjugate Vaccine Revenue by Application
  2. 6.1.1 Global Conjugate Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Conjugate Vaccine Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Conjugate Vaccine Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Conjugate Vaccine Sales by Application
  6. 6.2.1 Global Conjugate Vaccine Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Conjugate Vaccine Sales by Application (2021-2032) & (Million Unit)
  8. 6.2.3 Global Conjugate Vaccine Sales Market Share by Application (2021-2032)
  9. 6.3 Global Conjugate Vaccine Price by Application
7 Company Profiles
  1. 7.1 Pfizer
  2. 7.1.1 Pfizer Company Information
  3. 7.1.2 Pfizer Business Overview
  4. 7.1.3 Pfizer Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Pfizer Conjugate Vaccine Product Portfolio
  6. 7.1.5 Pfizer Recent Developments
  7. 7.2 GSK
  8. 7.2.1 GSK Company Information
  9. 7.2.2 GSK Business Overview
  10. 7.2.3 GSK Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 GSK Conjugate Vaccine Product Portfolio
  12. 7.2.5 GSK Recent Developments
  13. 7.3 Sanofi
  14. 7.3.1 Sanofi Company Information
  15. 7.3.2 Sanofi Business Overview
  16. 7.3.3 Sanofi Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Sanofi Conjugate Vaccine Product Portfolio
  18. 7.3.5 Sanofi Recent Developments
  19. 7.4 Merck
  20. 7.4.1 Merck Company Information
  21. 7.4.2 Merck Business Overview
  22. 7.4.3 Merck Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Merck Conjugate Vaccine Product Portfolio
  24. 7.4.5 Merck Recent Developments
  25. 7.5 Walvax Biotechnology
  26. 7.5.1 Walvax Biotechnology Company Information
  27. 7.5.2 Walvax Biotechnology Business Overview
  28. 7.5.3 Walvax Biotechnology Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Walvax Biotechnology Conjugate Vaccine Product Portfolio
  30. 7.5.5 Walvax Biotechnology Recent Developments
  31. 7.6 Royal (Wuxi) Bio-Pharmaceutical
  32. 7.6.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
  33. 7.6.2 Royal (Wuxi) Bio-Pharmaceutical Business Overview
  34. 7.6.3 Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Product Portfolio
  36. 7.6.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments
  37. 7.7 Bharat Biotech
  38. 7.7.1 Bharat Biotech Company Information
  39. 7.7.2 Bharat Biotech Business Overview
  40. 7.7.3 Bharat Biotech Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Bharat Biotech Conjugate Vaccine Product Portfolio
  42. 7.7.5 Bharat Biotech Recent Developments
  43. 7.8 Zhifei Biologic
  44. 7.8.1 Zhifei Biologic Company Information
  45. 7.8.2 Zhifei Biologic Business Overview
  46. 7.8.3 Zhifei Biologic Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Zhifei Biologic Conjugate Vaccine Product Portfolio
  48. 7.8.5 Zhifei Biologic Recent Developments
8 North America
  1. 8.1 North America Conjugate Vaccine Market Size by Type
  2. 8.1.1 North America Conjugate Vaccine Revenue by Type (2021-2032)
  3. 8.1.2 North America Conjugate Vaccine Sales by Type (2021-2032)
  4. 8.1.3 North America Conjugate Vaccine Price by Type (2021-2032)
  5. 8.2 North America Conjugate Vaccine Market Size by End Users
  6. 8.2.1 North America Conjugate Vaccine Revenue by End Users (2021-2032)
  7. 8.2.2 North America Conjugate Vaccine Sales by End Users (2021-2032)
  8. 8.2.3 North America Conjugate Vaccine Price by End Users (2021-2032)
  9. 8.3 North America Conjugate Vaccine Market Size by Country
  10. 8.3.1 North America Conjugate Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Conjugate Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Conjugate Vaccine Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Conjugate Vaccine Market Size by Type
  2. 9.1.1 Europe Conjugate Vaccine Revenue by Type (2021-2032)
  3. 9.1.2 Europe Conjugate Vaccine Sales by Type (2021-2032)
  4. 9.1.3 Europe Conjugate Vaccine Price by Type (2021-2032)
  5. 9.2 Europe Conjugate Vaccine Market Size by End Users
  6. 9.2.1 Europe Conjugate Vaccine Revenue by End Users (2021-2032)
  7. 9.2.2 Europe Conjugate Vaccine Sales by End Users (2021-2032)
  8. 9.2.3 Europe Conjugate Vaccine Price by End Users (2021-2032)
  9. 9.3 Europe Conjugate Vaccine Market Size by Country
  10. 9.3.1 Europe Conjugate Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Conjugate Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Conjugate Vaccine Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Conjugate Vaccine Market Size by Type
  2. 10.1.1 China Conjugate Vaccine Revenue by Type (2021-2032)
  3. 10.1.2 China Conjugate Vaccine Sales by Type (2021-2032)
  4. 10.1.3 China Conjugate Vaccine Price by Type (2021-2032)
  5. 10.2 China Conjugate Vaccine Market Size by End Users
  6. 10.2.1 China Conjugate Vaccine Revenue by End Users (2021-2032)
  7. 10.2.2 China Conjugate Vaccine Sales by End Users (2021-2032)
  8. 10.2.3 China Conjugate Vaccine Price by End Users (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Conjugate Vaccine Market Size by Type
  2. 11.1.1 Asia Conjugate Vaccine Revenue by Type (2021-2032)
  3. 11.1.2 Asia Conjugate Vaccine Sales by Type (2021-2032)
  4. 11.1.3 Asia Conjugate Vaccine Price by Type (2021-2032)
  5. 11.2 Asia Conjugate Vaccine Market Size by End Users
  6. 11.2.1 Asia Conjugate Vaccine Revenue by End Users (2021-2032)
  7. 11.2.2 Asia Conjugate Vaccine Sales by End Users (2021-2032)
  8. 11.2.3 Asia Conjugate Vaccine Price by End Users (2021-2032)
  9. 11.3 Asia Conjugate Vaccine Market Size by Country
  10. 11.3.1 Asia Conjugate Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Conjugate Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Conjugate Vaccine Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Conjugate Vaccine Market Size by Type
  2. 12.1.1 SAMEA Conjugate Vaccine Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Conjugate Vaccine Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Conjugate Vaccine Price by Type (2021-2032)
  5. 12.2 SAMEA Conjugate Vaccine Market Size by End Users
  6. 12.2.1 SAMEA Conjugate Vaccine Revenue by End Users (2021-2032)
  7. 12.2.2 SAMEA Conjugate Vaccine Sales by End Users (2021-2032)
  8. 12.2.3 SAMEA Conjugate Vaccine Price by End Users (2021-2032)
  9. 12.3 SAMEA Conjugate Vaccine Market Size by Country
  10. 12.3.1 SAMEA Conjugate Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Conjugate Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Conjugate Vaccine Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Conjugate Vaccine Value Chain Analysis
  2. 13.1.1 Conjugate Vaccine Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Conjugate Vaccine Production Mode & Process
  6. 13.2 Conjugate Vaccine Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Conjugate Vaccine Distributors
  9. 13.2.3 Conjugate Vaccine Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst